Healing peptides are short chains of amino acids promoted to speed recovery from tendon, muscle, joint, skin and gut injuries. The best known are BPC-157 and TB-500, followed by KPV, GHK-Cu and ARA-290. Most of their supporting evidence comes from rats, mice and cell cultures, and none is FDA-approved.[1][5]

This overview explains what these peptides are, how they are thought to work, what human studies actually show for tendons, joints and the gut, and where they stand with FDA and anti-doping rules in 2026.

What are healing peptides?

“Healing peptides” is a marketing label, not a medical drug class. It covers unrelated molecules that share one claim: helping damaged tissue repair itself. Some are fragments of natural proteins (TB-500 comes from thymosin beta-4, KPV from the hormone alpha-MSH), while BPC-157 is based on a protein in stomach juice.[5][2]

They differ from approved wound and injury treatments in one key way: none has been through the large, controlled trials FDA requires to show it works and is safe. A 2025 systematic review of BPC-157 for muscle, tendon, ligament and bone found 36 studies, of which 35 were preclinical (animal or lab) studies.[1] That pattern, impressive animal data with little human testing, runs through the whole category.

Browse all healing peptides

See all 9 healing peptides ↓

How healing peptides work

Each peptide works differently, and most mechanisms come from lab and animal research:

  • BPC-157 increased blood vessel growth and blood-flow recovery in rats, effects linked in lab studies to VEGFR2 and nitric oxide signaling.[13] FDA notes that its precise molecular targets have not been identified.[5]
  • TB-500 contains the actin-binding stretch of thymosin beta-4. A peptide containing that stretch sped skin wound repair in aged mice about as well as the full protein.[7]
  • KPV is absorbed into gut cells by the PepT1 transporter, where it blocked NF-kB, a major inflammation switch, in cell studies and reduced colitis in mice.[8]
  • GHK-Cu stimulated collagen production by skin cells grown in the lab at very low concentrations.[9]
  • ARA-290 activates the innate repair receptor, a pairing of the erythropoietin receptor with CD131 that is thought to calm inflammation after injury, without raising red blood cell counts.[12]

Tendons, joints and gut: what the research found

Tendons and ligaments

In rats with a cut Achilles tendon, daily BPC-157 produced stronger, better-organized tendons.[3] A 2026 rat study in Türkiye found TB-500 also increased tendon strength, but combining it with BPC-157 added nothing over either peptide alone.[6] No controlled human trial has tested either peptide for a tendon or ligament injury.

Joints

The main human data point is a chart review of 16 patients given BPC-157 knee injections (4 also received thymosin beta-4) at a single clinic: 14 reported improvement, but there was no comparison group and no validated scoring.[4] Across all human BPC-157 research, a 2026 review counted fewer than 30 participants in three small uncontrolled studies.[2]

Gut

BPC-157 was taken into clinical trials for inflammatory bowel disease,[3] yet a small multicenter trial of BPC-157 enemas in 53 people with ulcerative colitis did not clearly outperform placebo, according to FDA’s review, and was never fully published.[5] KPV taken by mouth reduced colitis in mice,[8] but FDA found no human data on KPV by any route.[5]

Skin wounds and nerves

GHK-Cu is better known for skin, but in 86 patients with venous leg ulcers a copper tripeptide cream did no better than placebo.[10] ARA-290 is the exception in this category: in a placebo-controlled trial in 38 people with sarcoidosis-related nerve fiber loss, it improved neuropathy symptoms and corneal nerve fiber area.[11]

How to read healing peptide claims

Three questions help separate evidence from marketing. First, was the study done in people? Most headline results, from tendon strength to colitis, come from rats or mice, and animal results often fail to carry over to humans.[14] Second, was there a comparison group? Uncontrolled reports such as the BPC-157 knee chart review cannot rule out placebo effects or natural healing over time.[4] Third, was the molecule the one being sold? Many claims about TB-500 come from trials of full-length thymosin beta-4, a much larger protein tested as eye drops or skin gel; FDA found no study in which TB-500 itself was given to people.[5]

Safety, legality and sports rules

FDA’s 2026 compounding decisions

  • Not approved: BPC-157, TB-500, KPV, GHK-Cu and ARA-290 are not part of any FDA-approved drug.[5][16]
  • Safety-risk list: FDA had placed BPC-157, the thymosin beta-4 fragment in TB-500, KPV and injectable GHK-Cu on its list of bulk substances that may present significant safety risks in compounding; in April 2026, after the nominations were withdrawn, FDA removed them. Removal is not an approval.[15]
  • July 2026: FDA’s staff recommended against BPC-157, TB-500 and KPV for compounding, but its advisory committee reportedly voted 8 to 6 in favor of each.[5][17] The vote is not binding, and no rule had followed as of our last review.
  • GHK-Cu and ARA-290: FDA is still evaluating non-injectable GHK-Cu, and it lists ARA-290 (cibinetide) among nominations made without adequate supporting information.[16]

Side effects and product risks

Human safety data are sparse. FDA described adverse event reports with BPC-157, including injection-site reactions and skin and gum darkening when used with TB-500, and found no toxicity studies of TB-500, or of KPV applied to the skin.[5] Because BPC-157 promotes blood vessel growth, doctors describe a theoretical concern that it could feed existing tumors; this has not been tested.[20] Products sold for “research use” are not made to pharmaceutical standards, and a 2026 review warns of contamination, mislabeling and dosing errors.[19]

Sports rules

WADA’s 2026 list bans BPC-157 at all times as a non-approved substance and prohibits thymosin beta-4 and derivatives such as TB-500. It also bans innate repair receptor agonists, the class that includes ARA-290. KPV and GHK-Cu are not named, but WADA’s S0 class bans any substance without government approval for human use.[18]

Several healing peptides overlap with other categories: GHK-Cu appears among peptides for skin, KPV and ARA-290 among immune peptides, and TB-500 among performance peptides.